Spectrophotometric and HPLC determination of secnidazole in pharmaceutical tablets.

Simple and accurate spectrophotometric and HPLC methods were developed for the determination of secnidazole in tablets dosage form. The first spectrophotometric method depends on the reduction of secnidazole molecule with zinc dust and hydrochloric acid followed by condensation with either p-dimethylaminobenzaldehyde or anisaldehyde to give colored chromogens having absorbance at 494 and 398 nm, respectively. The second method was based on the reaction of the drug with sodium nitroprusside in the presence or absence of hydroxylammonium hydrochloride. The formed colored chromogens were measured at 584 and 508 nm, respectively. The experimental conditions were optimized and Beer's law was obeyed over the applicable concentration ranges. The application of HPLC procedures depended on using either a conventional or microbore reverse-phase (C18) column along with mobile phases consisting of water and methanol (30:70), at pH of 3.5. Both techniques were applied successfully for the analysis of secnidazole in tablets form. The results obtained from both procedures were statistically compared using the Student's-t and F-variance ratio tests.

Spectrophotometric methods for the determination of benazepril hydrochloride in its single and multi-component dosage forms.

Three sensitive and accurate methods are presented for the determination of benazepril in its dosage forms. The first method uses derivative spectrophotometry to resolve the interference due to formulation matrix. The second method depends on the color formed by the reaction of the drug with bromocresol green (BCG). The third one utilizes the reaction of benazepril, after alkaline hydrolysis, with 3-methylbenzothialozone (MBTH) hydrazone where the produced color is measured at 593 nm. The latter method was extended to develop a stability-indicating method for this drug. Moreover, the derivative method was applied for the determination of benazepril in its combination with hydrochlorothiazide. The proposed methods were applied for the analysis of benazepril in the pure form and in tablets. The coefficient of variation was less than 2%.

Spectrophotometric and spectrofluorometric methods for the assay of lisinopril in single and multicomponent pharmaceutical dosage forms.

Simple and sensitive methods are described for the assay of lisinopril in tablets. The first method (A) is based on the reaction of the drug with chloranil in aqueous solution of pH 9.5 to give yellow colour measured at 346 nm. The second method (B) is based upon the interaction of lisinopril with dichlone resulting in the formation of an intense purple colour measured at 580 nm. The third method (C) depends on the reaction of the drug with acetylacetone and formaldehyde to form a coloured condensation product measured at 356 nm and also has a strong fluorescence at 475 nm (lambda(ex) 410 nm). This method is extended to determine lisinopril in binary mixtures with hydrochlorothiazide. The last method (D) depends on measuring the first and second derivative spectra of lisinopril. Moreover, the derivative method is used as stability-indicating method where lisinopril can be determined in presence of its degradation products. The proposed methods proved to be suitable for a rapid quality control of commercial dosage forms. The results obtained were precise and accurate.

Simultaneous determination of melatonin-pyridoxine combination in tablets by zero-crossing derivative spectrophotometry and spectrofluorimetry.

Two methods have been developed for the analysis of melatonin (M) and pyridoxine hydrochloride (PH) in combination. The first method depends on first- and second-derivative ultraviolet spectrophotometry, with the zero crossing technique of measurement. First-derivative amplitudes at 296 nm and second-derivative amplitudes at 294 and 322 nm are selected for the determination of M and PH, respectively. The second method is based on the native fluorescence of both M and PH, in methanol and 0.1 M hydrochloric acid, respectively, after a preliminary solvent extraction procedure. The relative standard deviation of both methods was less than 2.0%. The two methods have been successfully applied to the determination of both drugs in laboratory-prepared mixtures and in tablets.

Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography.

Derivative spectrophotometry and high-performance liquid chromatography (HPLC) were used to determine tenoxicam and one of its decomposition products (2-aminopyridine) simultaneously and in the presence of each other. The derivative procedure was based on the linear relationship between the tenoxicam concentration and the second derivative amplitudes at 390-348 nm (peak-to-trough) measurement. The 2-aminopyridine was determined through measuring the second derivative amplitude at 241 nm (zero-crossing for tenoxicam). For the HPLC procedure, a reversed-phase C8 column with a mobile phase composed of 0.02 M sodium acetate-methanol-acetonitrile (11:8:1) with 0.005 M heptane sulfonic acid sodium salt, as an ion pair, was used to separate both compounds with 2,4-dinitrochlorobenzene, as an internal standard, in reasonable time. The flow rate was 1.5 ml min-1 with a programmable ultraviolet (UV) detection at 300 and 375 nm. Both UV derivative spectrophotometric and HPLC approaches were followed for confirming the purity of tenoxicam in bulk and tablets dosage form.

Spectrophotometric determination of acrivastine in urine and capsules.

Three sensitive and accurate spectrophotometric methods are presented for the determination of the antihistaminic acrivastine (ACR) in capsules and urine. The first method utilizes the reaction of 2-nitrophenylhydrazine hydrochloride in presence of dicyclohexylcarbodiimide and pyridine. The violet colour of the resulting acid hydrazide is measured at 550 nm. The second method is based on alkaline oxidation of the drug with potassium permanganate and subsequent measurement of the formed manganate ion at 608 nm. The third method uses derivative spectrophotometry for the determination of ACR. The last method is extended to the in vitro determination of the drug in urine. All methods gave a relative standard deviation of less than 2%.